{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:15:06Z","timestamp":1786119306512,"version":"build-2736575974"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1097\/coc.0b013e3181c4c531","type":"journal-article","created":{"date-parts":[[2010,3,27]],"date-time":"2010-03-27T05:24:09Z","timestamp":1269667449000},"page":"2-5","source":"Crossref","is-referenced-by-count":0,"title":["Age Has No Significant Impact on Overall Survival and on Treatment Tolerability in Relapsed Stage IV Cutaneous Malignant Melanoma Patients Receiving Cisplatin, Gemcitabine, and Treosulfan"],"prefix":"10.1097","volume":"34","author":[{"given":"Jens","family":"Atzpodien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Terfloth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fluck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Reitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210128","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S1470-2045(02)00730-1","article-title":"A case for geriatric oncology.","volume":"3","author":"Repetto","year":"2002","journal-title":"Lancet Oncol"},{"key":"R2-2-20210128","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.critrevonc.2003.06.006","article-title":"Aging and the hemopoietic system.","volume":"48S","author":"Pinto","year":"2003","journal-title":"Crit Rev in Oncol\/Hematol"},{"key":"R4-2-20210128","first-page":"21","article-title":"Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.","volume":"19","author":"Serrone","year":"2000","journal-title":"J Exp Clin Cancer Res"},{"key":"R5-2-20210128","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1038\/sj.bjc.6602586","article-title":"Phase I trial combining gemcitabine and treosulfan in advanced cutaneous and uveal melanoma patients.","volume":"92","author":"Corrie","year":"2005","journal-title":"Br J Cancer"},{"key":"R6-2-20210128","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/978-3-642-19022-3_8","article-title":"Chemosensitivity testing malignant melanoma.","volume":"161","author":"Ugurel","year":"2003","journal-title":"Recent Results Cancer Res"},{"key":"R7-2-20210128","doi-asserted-by":"crossref","first-page":"5454","DOI":"10.1158\/1078-0432.CCR-05-2763","article-title":"In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group.","volume":"12","author":"Ugurel","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R8-2-20210128","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/00001813-199906000-00002","article-title":"Heterogeneity of chemosensitivity of metastatic cutaneous melanoma.","volume":"10","author":"Cree","year":"1999","journal-title":"Anticancer Drugs"},{"key":"R9-2-20210128","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/sj.bjc.6604045","article-title":"Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients.","volume":"97","author":"Atzpodien","year":"2007","journal-title":"Br J Cancer"},{"key":"R10-2-20210128","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1200\/JCO.2001.19.16.3622","article-title":"Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on cancer melanoma staging system.","volume":"19","author":"Balch","year":"2001","journal-title":"J Clin Oncol"},{"key":"R11-2-20210128","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/BF02303614","article-title":"Age as a prognostic factor in the malignant melanoma population.","volume":"1","author":"Austin","year":"1994","journal-title":"Ann Surg Oncol"},{"key":"R12-2-20210128","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1001\/archderm.1991.01680070088011","article-title":"Invasive cutaneous melanoma in elderly patients.","volume":"127","author":"Loggie","year":"1991","journal-title":"Arch Dermatol"},{"key":"R13-2-20210128","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1245\/ASO.2004.04.015","article-title":"Correlation between prognostic factors and increasing age in melanoma.","volume":"11","author":"Chao","year":"2004","journal-title":"Ann Surg Oncol"},{"key":"R15-2-20210128","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1200\/JCO.2001.19.16.3635","article-title":"Final version of the American Joint Committee on cancer staging system for cutaneous melanoma.","volume":"19","author":"Balch","year":"2001","journal-title":"J Clin Oncol"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00000421-201102000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:14:29Z","timestamp":1786040069000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000421-201102000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0b013e3181c4c531","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2011,2]]}}}